Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 10 | 2024 | 406 | 2.300 |
Why?
|
| Endometrial Neoplasms | 9 | 2025 | 79 | 1.870 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 415 | 1.770 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2025 | 150 | 1.610 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 17 | 1.400 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2022 | 44 | 1.220 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 51 | 0.970 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 22 | 0.860 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2021 | 19 | 0.780 |
Why?
|
| Female | 49 | 2025 | 24018 | 0.750 |
Why?
|
| Infertility | 1 | 2022 | 21 | 0.740 |
Why?
|
| Aged | 27 | 2025 | 7982 | 0.710 |
Why?
|
| Humans | 66 | 2025 | 42163 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 209 | 0.680 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 20 | 0.670 |
Why?
|
| Middle Aged | 32 | 2025 | 11819 | 0.660 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 336 | 0.620 |
Why?
|
| Community Health Services | 4 | 2017 | 207 | 0.620 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 366 | 0.620 |
Why?
|
| Residence Characteristics | 3 | 2018 | 359 | 0.620 |
Why?
|
| Violence | 2 | 2018 | 133 | 0.610 |
Why?
|
| Retrospective Studies | 10 | 2024 | 2485 | 0.590 |
Why?
|
| Poverty | 3 | 2016 | 395 | 0.520 |
Why?
|
| Cohort Studies | 7 | 2024 | 1729 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 188 | 0.500 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 208 | 0.490 |
Why?
|
| Medically Uninsured | 2 | 2016 | 64 | 0.490 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1679 | 0.460 |
Why?
|
| Albuminuria | 2 | 2012 | 78 | 0.440 |
Why?
|
| Adult | 26 | 2025 | 13458 | 0.430 |
Why?
|
| Myometrium | 1 | 2014 | 15 | 0.430 |
Why?
|
| Cisplatin | 3 | 2024 | 91 | 0.420 |
Why?
|
| Lymph Nodes | 1 | 2014 | 73 | 0.420 |
Why?
|
| Urban Health Services | 1 | 2014 | 43 | 0.420 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 18 | 0.420 |
Why?
|
| Multilingualism | 1 | 2014 | 50 | 0.410 |
Why?
|
| Immunotherapy | 2 | 2025 | 137 | 0.410 |
Why?
|
| Neoplasms | 5 | 2015 | 1341 | 0.380 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 250 | 0.380 |
Why?
|
| Los Angeles | 9 | 2023 | 390 | 0.360 |
Why?
|
| SEER Program | 3 | 2017 | 157 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 239 | 0.330 |
Why?
|
| Survival Rate | 4 | 2021 | 353 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 959 | 0.330 |
Why?
|
| Health Status Disparities | 4 | 2015 | 705 | 0.310 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 350 | 0.290 |
Why?
|
| Mass Screening | 1 | 2012 | 531 | 0.290 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 31 | 0.280 |
Why?
|
| Prognosis | 7 | 2025 | 850 | 0.270 |
Why?
|
| Quality of Health Care | 1 | 2008 | 158 | 0.260 |
Why?
|
| Patient Care Management | 1 | 2006 | 5 | 0.260 |
Why?
|
| Social Welfare | 1 | 2006 | 29 | 0.260 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 40 | 0.250 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 97 | 0.250 |
Why?
|
| Male | 24 | 2020 | 22779 | 0.240 |
Why?
|
| Peritoneum | 1 | 2025 | 9 | 0.240 |
Why?
|
| Long-Term Care | 2 | 2022 | 55 | 0.240 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 428 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2025 | 53 | 0.230 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2024 | 5 | 0.230 |
Why?
|
| Health Education | 1 | 2008 | 358 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2025 | 28 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 8 | 0.220 |
Why?
|
| Clinical Medicine | 1 | 2004 | 7 | 0.220 |
Why?
|
| Health Services | 1 | 2004 | 62 | 0.220 |
Why?
|
| Incidence | 3 | 2024 | 1054 | 0.210 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 23 | 0.210 |
Why?
|
| Medicaid | 2 | 2007 | 138 | 0.210 |
Why?
|
| Young Adult | 8 | 2020 | 4936 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 23 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 94 | 0.200 |
Why?
|
| Health Services Research | 1 | 2004 | 161 | 0.200 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 249 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 2803 | 0.200 |
Why?
|
| United States | 8 | 2025 | 5072 | 0.200 |
Why?
|
| Histones | 1 | 2024 | 194 | 0.200 |
Why?
|
| Progesterone Reductase | 1 | 2022 | 1 | 0.200 |
Why?
|
| Steroid Isomerases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Chromatin | 1 | 2024 | 179 | 0.200 |
Why?
|
| Adipokines | 1 | 2022 | 25 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2021 | 845 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 233 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 512 | 0.190 |
Why?
|
| Alopecia | 1 | 2022 | 10 | 0.190 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 81 | 0.190 |
Why?
|
| Cell Nucleus | 1 | 2024 | 383 | 0.190 |
Why?
|
| Multienzyme Complexes | 1 | 2022 | 69 | 0.190 |
Why?
|
| Disinfection | 1 | 2022 | 10 | 0.190 |
Why?
|
| Infection Control | 1 | 2022 | 17 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 3077 | 0.180 |
Why?
|
| Adolescent | 9 | 2020 | 5950 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 290 | 0.180 |
Why?
|
| Cross Infection | 1 | 2022 | 47 | 0.180 |
Why?
|
| Insurance Coverage | 2 | 2016 | 108 | 0.180 |
Why?
|
| Genitalia, Female | 1 | 2021 | 29 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 532 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 64 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 729 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Drug Interactions | 1 | 2021 | 151 | 0.170 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 58 | 0.170 |
Why?
|
| Models, Statistical | 1 | 2021 | 190 | 0.170 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 11 | 0.160 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 16 | 0.160 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 82 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 7 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2021 | 253 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1051 | 0.150 |
Why?
|
| Health Personnel | 1 | 2022 | 262 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 215 | 0.150 |
Why?
|
| Chagas Disease | 1 | 2020 | 101 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 744 | 0.150 |
Why?
|
| Midwestern United States | 1 | 2018 | 21 | 0.150 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 1554 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2019 | 99 | 0.150 |
Why?
|
| Risk | 2 | 2021 | 289 | 0.140 |
Why?
|
| Developing Countries | 2 | 2009 | 112 | 0.140 |
Why?
|
| Patient Selection | 2 | 2021 | 192 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2022 | 377 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 284 | 0.140 |
Why?
|
| Allostasis | 1 | 2017 | 22 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 222 | 0.130 |
Why?
|
| Risk Factors | 6 | 2024 | 3942 | 0.130 |
Why?
|
| Sex Factors | 2 | 2018 | 1008 | 0.130 |
Why?
|
| Religion | 1 | 2017 | 90 | 0.130 |
Why?
|
| Pregnancy | 1 | 2022 | 1737 | 0.130 |
Why?
|
| Qualitative Research | 2 | 2017 | 526 | 0.120 |
Why?
|
| Chicago | 1 | 2016 | 30 | 0.120 |
Why?
|
| Social Class | 2 | 2016 | 286 | 0.120 |
Why?
|
| Perception | 2 | 2015 | 209 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 174 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 163 | 0.120 |
Why?
|
| Research Subjects | 1 | 2015 | 34 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 116 | 0.110 |
Why?
|
| Voice | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pitch Discrimination | 1 | 2014 | 3 | 0.110 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 573 | 0.110 |
Why?
|
| Health Behavior | 3 | 2015 | 568 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 32 | 0.110 |
Why?
|
| Delphi Technique | 1 | 2014 | 30 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 84 | 0.100 |
Why?
|
| Trust | 1 | 2015 | 157 | 0.100 |
Why?
|
| San Francisco | 2 | 2023 | 34 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2014 | 135 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 237 | 0.100 |
Why?
|
| Language | 1 | 2014 | 181 | 0.100 |
Why?
|
| HIV Infections | 1 | 2006 | 2535 | 0.090 |
Why?
|
| Health Status | 1 | 2016 | 432 | 0.090 |
Why?
|
| Registries | 3 | 2020 | 431 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1139 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 303 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2016 | 541 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 79 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 1848 | 0.090 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Feeding Behavior | 2 | 2012 | 461 | 0.090 |
Why?
|
| Health Promotion | 1 | 2017 | 691 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 16 | 0.090 |
Why?
|
| Hypertension | 3 | 2019 | 823 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 234 | 0.080 |
Why?
|
| Fatigue | 1 | 2011 | 97 | 0.080 |
Why?
|
| Universities | 1 | 2014 | 539 | 0.080 |
Why?
|
| Self Care | 1 | 2011 | 173 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 599 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 234 | 0.080 |
Why?
|
| Snake Bites | 1 | 2009 | 2 | 0.080 |
Why?
|
| Zoonoses | 1 | 2009 | 20 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2025 | 1574 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 467 | 0.070 |
Why?
|
| Leptospirosis | 1 | 2009 | 30 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 102 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 24 | 0.070 |
Why?
|
| Health Surveys | 2 | 2008 | 401 | 0.070 |
Why?
|
| Consensus | 1 | 2008 | 53 | 0.070 |
Why?
|
| Education | 1 | 2008 | 60 | 0.070 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1221 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 641 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 2598 | 0.070 |
Why?
|
| Food Supply | 1 | 2008 | 120 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 238 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2007 | 143 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 32 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 16695 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 225 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2024 | 46 | 0.050 |
Why?
|
| Capital Financing | 1 | 2004 | 2 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 285 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2015 | 916 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2005 | 168 | 0.050 |
Why?
|
| Cadherins | 1 | 2005 | 102 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 35 | 0.050 |
Why?
|
| Methylation | 1 | 2024 | 118 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 32 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2004 | 32 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 358 | 0.050 |
Why?
|
| Prevalence | 3 | 2019 | 1597 | 0.050 |
Why?
|
| Teaching | 1 | 2004 | 58 | 0.050 |
Why?
|
| Public Health | 1 | 2008 | 405 | 0.050 |
Why?
|
| Taxes | 1 | 2023 | 14 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 136 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 59 | 0.050 |
Why?
|
| Protein Transport | 1 | 2024 | 295 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 78 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 64 | 0.050 |
Why?
|
| Child | 2 | 2022 | 3381 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 339 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 29 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 228 | 0.050 |
Why?
|
| Adiponectin | 1 | 2022 | 59 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 15 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 1 | 0.050 |
Why?
|
| Mice | 2 | 2024 | 6490 | 0.050 |
Why?
|
| Fomites | 1 | 2022 | 3 | 0.050 |
Why?
|
| Disinfectants | 1 | 2022 | 8 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.050 |
Why?
|
| Androgens | 1 | 2022 | 107 | 0.050 |
Why?
|
| New York | 1 | 2022 | 88 | 0.050 |
Why?
|
| Leptin | 1 | 2022 | 118 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 118 | 0.040 |
Why?
|
| Risk-Taking | 2 | 2015 | 456 | 0.040 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2021 | 20 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1068 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 205 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 51 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 67 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 39 | 0.040 |
Why?
|
| Bolivia | 1 | 2020 | 9 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 317 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 336 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 71 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2020 | 57 | 0.040 |
Why?
|
| Endometrium | 1 | 2020 | 60 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 332 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 26 | 0.040 |
Why?
|
| Gynecology | 1 | 2019 | 33 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 45 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 83 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 708 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 456 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 154 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 363 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1058 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 534 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 661 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 352 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 393 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 107 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1143 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 183 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 725 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 979 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 31 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 810 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 8 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 56 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1516 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 66 | 0.030 |
Why?
|
| Pitch Perception | 1 | 2014 | 2 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 141 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 24 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 1586 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1131 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 508 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2014 | 50 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 132 | 0.030 |
Why?
|
| Nerve Net | 1 | 2014 | 96 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2014 | 160 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 57 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Integrative Medicine | 1 | 2011 | 8 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 62 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 123 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 225 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 34 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 5 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 577 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 398 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 180 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 733 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 502 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 243 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 233 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 2 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 11 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 47 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 32 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 428 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 50 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 99 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 438 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 46 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 90 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 225 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 36 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 487 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 207 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 263 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 587 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 674 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2005 | 11 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 638 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 170 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 326 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 362 | 0.010 |
Why?
|
| Mexico | 1 | 2005 | 286 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 928 | 0.010 |
Why?
|